condition, and most patients are easily treated by simple trephination and drainage. 3, 23, 25 However, various complications, such as acute hematoma, infection, seizure, cerebral edema, tension pneumocephalus, and failure of the brain to expand due to cerebrocranial disproportion, may develop after CSDH drainage. 15, 22, 28 Thus, alternative and more conservative therapies may be necessary for patients who are at higher risk for complications or are likely to have poor outcomes after surgery.
It is well known that impaired angiogenesis in the neomembrane and localized inflammation influence CSDH formation to a large extent. 8, 10 Atorvastatin is known to have antiinflammatory effects and to promote angiogenesis in addition to lowering cholesterol. 1, 2, 9, 12, 18, 21 Recent research in rats has demonstrated that atorvastatin treatment may eliminate SDH and improve neural function through its antiinflammatory and proangiogenesis effects. 16 However, further evidence from clinical trials is needed to guide the use of atorvastatin in the treatment of CSDH in humans.
Although results from a preliminary clinical study showed that the oral administration of atorvastatin was safe and effective in treating CSDH, not all of the patients in that study were able to avoid surgery. 30 Our aim in the present study was to analyze the effect of atorvastatin in the management of CSDH and identify those patients sensitive to atorvastatin therapy.
methods patients
This prospective, observational study included 80 patients with evidence of CSDH who were enrolled from February 2012 to August 2014 under a human subject protocol approved by the Jiangsu University Hospital Medical Ethics Board. All patients and/or their family members were thoroughly informed of the research and its risks. Informed consent was obtained from each patient or the patient's legal representative.
Clinical data, including age, sex, head injury history, medical history, and presence of hemiparesis, were obtained on the day of diagnosis. The patients' neurological condition was graded using the Markwalder grading scale and Glasgow Coma Scale (GCS) at admission and during routine clinic visits. 20, 27 The grading system is shown in Table 1 . Because of the risk of brain herniation associated with increased intracranial pressure (Grade 4), this study included only patients whose condition was classified as Grade 0-3.
The patients' level of dependence in activities of daily living was assessed with the modified Barthel Index (mBI).
14 The mBI evaluates the ability of a patient with respect to feeding, bathing, grooming (face washing, tooth brushing, shaving, and hair combing), dressing (tying shoes and fastening buttons), toileting (defecation, urination), self-cleaning (adjusting clothing and washing with water), going to bed, moving a chair, and mobility (walking on a flat floor and going up and down a flight of stairs). On the basis of their responses, patients are classified into one of the following categories: independent (scores of 95-100), slightly dependent (scores of 90-80), moderately dependent (scores of 75-65), severely dependent (scores of 60-45), or completely dependent (scores of 0-40).
inclusion and exclusion criteria
In order to be considered for inclusion in the study, patients had to be 18 years of age or older and have CT evidence of supratentorial CSDH. Patients with the following conditions were excluded: a high risk of brain herniation and/or the necessity of immediate surgical intervention; liver malfunction with an increase in alanine aminotransferase (> 40 U/L) and aspartate aminotransferase (> 46 U/L) in peripheral blood samples; bleeding tendency, defined as prothrombin time > 15 seconds, international normalized ratio (INR) > 1.5, activated partial thromboplastin time > 40.0 seconds, plasma fibrinogen > 4.0 g/L, or thrombin time > 25 seconds; CSDH resulting from tumor or blood disease; treatment with angiotensin converting enzyme inhibitor, estrogen, etizolam, or steroids that may influence angiogenesis and promote blood circulation within 2 weeks prior to the enrollment; and refusal to participate in the study.
design and atorvastatin therapy
Three medical assistants with specialized training were appointed the study coordinators and managed the group assignments. All patients were randomly assigned to the group treated with atorvastatin or the control group, with randomization based on the coin-tossing method. Patients in the atorvastatin group took a single oral dose of 20 mg atorvastatin daily (Lipitor, Pfizer, Inc.) for 1-6 months. Patients in the control group took a placebo pill on the same dosing schedule. Previous work has shown that the most potent angiogenesis facilitation without the risk of hemorrhage is initiated by a low dosage of atorvastatin, so in our study, the 20-mg dosage was chosen. 4, 11, 29 Patients' neurological function was evaluated before treatment and during treatment at 1 week, 2 weeks, 1 month, 3 months, and 6 months after initiation of placebo or atorvastatin therapy. Patients' blood cell counts, coagulation parameters, and liver, kidney, neurological system, and gastrointestinal tract function were monitored, as were any symptoms that might be related to the medication during the course of treatment.
The criteria for switching a patient from atorvastatin or placebo treatment to surgery included the following: a decrease in GCS score ≥ 2, a deterioration in Markwalder grade by 1 grade or more, a sudden increase in hematoma volume ≥ 10%, or a midline displacement of the brain of more than 1 cm as demonstrated by CT. Time to surgery was defined as time from study enrollment (and initiation of treatment) to surgery. Atorvastatin treatment was discontinued when a hematoma disappeared completely in the setting of stable neurological status for 1 month.
evaluation and Follow-up
Each patient had a CT scan of the head at the baseline before treatment. Hematoma volume was calculated based on the Coniglobus formula, given as: hematoma volume (cm 3 ) = 1/2 × the longest diameter of the hematoma layer with the largest area (cm) × the longest diameter perpendicular to the longest diameter (cm) × the thickness of the hematoma (cm). If a patient had more than 1 hematoma, a total volume of multiple hematomas was calculated. The hematoma collection was classified as hypodense, isodense, hyperdense, or mixed, on the basis of the density of hematoma relative to brain tissue. 26 CT examinations were also performed routinely 1, 3, 6, and 12 months after initiation of treatment to calculate hematoma volume. If necessary, additional CT scans were performed.
Markwalder grades and mBI scores for activities of daily living (ADL) were obtained before and after the treatment. Complications and adverse events were documented. The secondary outcome measure was recurrence at 12 months, defined as occurrence of symptoms or signs attributable to a new ipsilateral hematoma seen on a CT scan.
statistical analysis
Data were presented as mean ± SD or numbers of patients and percentage. The Student t-test or linear trend chi-square test was used to evaluate differences between groups. Multiple logistic regression models were used to determine correlations between continuous or categorical variables and independent factors affecting the need for surgery. All statistical analyses were carried out using PASW Statistics for Windows version 18.0 (SPSS, Inc.), and significance was defined as a p value < 0.05.
results
The flow diagram in Fig. 1 shows the progress of patients from initial assessment for eligibility through followup. All patients were randomly assigned to the atorvastatin group (46 patients) or the control group (34 patients). The demographic and clinical characteristics of the patients are summarized in Table 2 . The groups were well matched. The mean age of the participants was 65.41 ± 10.84 years (range 40-84 years). There were 65 men and 15 women (sex ratio 4.3:1). As expected, the atorvastatin group had a significantly lower rate of surgical decompression (p = 0.001). Interestingly, the mean time to surgery for the patients who required surgery was longer in the atorvastatin group than in the control group (p = 0.018). The atorvastatin group and control group were similar with respect to age, sex, history of head injury, medical history, Markwalder grades, mBI scores (dependency status), hemiparesis symptoms, and CT findings at admission ( Table 2) . Detailed information regarding the reasons for the switch to surgery and hematoma volume before surgery in the 2 groups is provided in Table 3 . Table 4 shows a comparison of the baseline characteristics of patients in the atorvastatin group stratified by the need for surgery (i.e., patients who required surgery vs those for whom conservative treatment was successful). There was no statistically significant difference between the 2 subgroups with respect to demographic variables such as age, head injury, and medical history. The female/ male ratio was significantly higher in the no-surgery group than in the surgery group (p = 0.016). The distribution of Markwalder grades and levels of dependency in ADL as well as the prevalence of hemiparesis at admission differed significantly between groups (p = 0.002, p = 0.001, and p = 0.001, respectively). Although the hematoma density and position on admission CT scans did not differ significantly between the 2 subgroups, the mean hematoma volume was significantly greater in the surgery group (p = 0.012).
After adjustment for age, sex, admission Markwalder grade, level of dependency in ADL, neurological deficit (hemiparesis), and hematoma volume, the results of logistic regression analysis showed that atorvastatin significantly reduced the probability of switch to surgery in all patients; no other factor had a significant association with atorvastatin treatment (Table 5) . With the logistic regression model, unfavorable Markwalder grade (Grades 2-4) and level of dependency in ADL (severely or completely dependent) were identified to increase and female sex, as an independent factor, to decrease the probability of switch to surgery in the atorvastatin group (Table 5) . Further analysis showed that there was a positive interaction between female sex and atorvastatin (p = 0.007) ( Table 5) .
Among the 46 patients in the atorvastatin group, 26 (56.5%) were able to avoid surgery. Two asymptomatic patients in the control group had no hematoma enlargement during the 12 months of observation. Unfortunately, however, 2 patients in the control group suffered acute hematomas after bur hole drainage and had serious deterioration of neurological status at 1-month follow-up. In 1 of these cases, the patient had bur hole drainage 9 days after enrolling in the study, and at 1-month follow-up, his neurological condition was classified as Grade 2 and he was moderately dependent. Fortunately, his neurological condition had returned to normal by the 3-month follow- Patient stuporous but responding appropriately to noxious stimuli; severe focal signs, such as hemiplegia 4
Patient comatose with absent motor responses to painful stimuli; decerebrate or decorticate posturing up visit. In the other case, the patient's condition was completely dependent, with Grade 3 neurological condition at 1 month after study enrollment, and this patient was then lost to follow-up. There was no recurrent hematoma during the course of follow-up in either group. A typical hematoma absorption process for atorvastatin therapy is shown in Fig. 2 , and Fig. 3 shows serial CT scans in a representative case in which atorvastatin treatment was not successful and surgery was required. During the course of therapy, there were no significant changes in blood cell counts or hematological or liver function (data not shown). No documented atorvastatinrelated side effects were observed.
discussion
The aim of this study was to determine the effect of atorvastatin in the management of CSDH and identify characteristics of patients who respond to atorvastatin therapy. The results indicated that patients treated with atorvastatin had a lower rate of switching to surgery, and in those cases in which surgery was required despite atorvastatin treatment, the mean time to surgery (measured from enrollment in the study) was longer than in the control group. Univariate analysis showed that sex and admission Markwalder grade, degree of dependency in ADL, presence of hemiparesis, and hematoma volume were related to the requirement for surgery in the atorvastatin group. Additionally, after adjustment for the other variables, the results of logistic regression analysis showed that atorvastatin significantly reduced the probability of surgery and that female sex and favorable admission Markwalder grade and level of dependence in ADL (mBI score) were independent protective factors for not needing surgery during the follow-up period.
Atorvastatin, one of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, is a first-line therapy for patients with high cholesterol levels and has been demonstrated to improve angiogenesis and increase circulating endothelial progenitor cells, which are critical for the formation of new blood vessels. 32 It has also been shown to inhibit inflammation and decrease levels of pro-inflamma- 1 Prior studies have demonstrated that the most potent angiogenesis facilitation without risk of hemorrhage was initiated by a low dose and not a high dose of atorvastatin. 4, 11, 29 CSDH patients responded well to the dose of 20 mg daily atorvastatin, 30 so this dose was chosen for use in the present study.
To date, published studies of atorvastatin in the treatment of CSDH have been rare. No previous study has included placebo-controlled comparison or nonoperative management without atorvastatin during treatment periods. Also, the population sensitive to atorvastatin has never been characterized. This is the first study to prospectively evaluate the effect of atorvastatin on CSDH using a placebo-controlled comparison and to identify the subset of patients who respond positively to atorvastatin.
Our findings agree with results from one other prospective study. Dong Wang and coworkers 30 reported that almost all (22/23, 95%) of the patients with CSDH who were treated with atorvastatin in their study experienced significant improvements in hematoma volume, neurological deficits, and dependency in activities of daily living. Improvements were observed early in the treatment and pro- gressed to complete hematoma resolution in 22 patients. These findings are consistent with a positive effect of atorvastatin in prevention of switching to surgery, and the use of atorvastatin could prevent some devastating complications associated with surgical intervention. In our study, significant differences in the time to surgery and the rate of switching to surgery between the atorvastatin group and the control group support the effectiveness of atorvastatin therapy for CSDH. However, the logistic regression model identified atorvastatin as a factor strongly associated with requirement for surgery, and only 26 (56.5%) of the 46 patients treated with atorvastatin were able to avoid bur hole drainage. Based on these results, we conclude that not all of our CSDH patients were appropriate candidates for atorvastatin therapy. It is understandable that favorable admission Markwalder grading scale and mBI scores had a close relationship with successful nonoperative management. Good admission scores might mean more time for the effects of atorvastatin on angiogenesis and inflammation. CSDH patients with unfavorable scores usually suffer with various disabling symptoms, such as cognitive dysfunction, severe headache, and hemiparesis, and often have to undergo surgery because of deterioration in their condition caused by hematoma enlargement before atorvastatin therapy can be effective.
We were surprised by the presence of a sex difference between the surgery and no-surgery subgroups of the patients treated with atorvastatin. In a previous study, higher concentrations of estradiol and progesterone receptors were observed in the hematoma external membrane (HEM) in male CSDH patients; thus the effect of estrogens on the newly vascularized HEM tended to cause an increased formation of tissue plasminogen activator (tPA), which, if it escapes into the subdural collection, could maintain a local hyperfibrinolysis.
5 Nevertheless, the mechanisms by which estrogens may affect atorvastatin treatment for CSDH are still unclear, and further experimental and clinical studies are needed to verify whether sex hormone factors might be involved.
The use of antithrombotic agents, either antiplatelet agents or anticoagulants, is a significant risk factor for the development of chronic subdural hematomas. 7 Thus, patients with any bleeding tendency were excluded from our study. Additionally, aspirin or warfarin therapy was discontinued after enrollment. Interestingly, however, we found a higher rate of prior aspirin or warfarin use in patients who were treated successfully with atorvastatin compared with those in the atorvastatin group who required surgery (Table 4 , p = 0.080), although the difference was not significant. As is commonly known, aspirin has a powerful antiinflammatory effect. Taking this into account, it is not surprising that aspirin may play a role in enhancing the antiinflammatory effect of atorvastatin. The results of the present study, however, are not sufficient to draw conclusions about the effect of such an interaction on CSDH.
Nearly all patients had favorable Markwalder grades and mBI scores after atorvastatin or surgery therapy at 1-12 months follow-up (Table 6 ). Although resolution of CSDH may occur spontaneously without treatment, 6, 19 no patient in our study appeared to undergo spontaneous resolution. However, hematoma remained unchanged in 2 patients in the control group under intensive observation, and these patients were able to avoid surgery during the follow-up period. Unfortunately, surgical complications occurred in our study; 2 patients suffered acute hematomas after bur hole drainage and had severe neurological deficit at 1-month follow-up. There was no recurrence of CSDH during follow-up in our study; because of the small sample size, it is difficult to estimate whether atorvastatin treatment would be more effective than surgery in preventing recurrence. The present study was not a double-blind study. Therefore, it was potentially subject to sources of bias and variation. Three medical assistants were appointed the study coordinators, and they managed the group assignments and provision of active drug or placebo to the enrolled patients. Although the patients were not aware of their groups, we did not guarantee that the treating surgeons were blinded to group assignment. Therefore some objective criteria were used to decide whether to perform surgery: the level of consciousness was assessed with GCS, deterioration in symptoms with the Markwalder grading scale, and hematoma volume with CT. Further multicenter, large sample size, randomized and controlled trials are needed to confirm these results.
conclusions
Surgery is recommended for patients with severe initial signs or symptoms related to CSDH, such as hemiparesis and elevated intracranial pressure. The results of the present study indicate that atorvastatin administration can promote the resolution of CSDH, especially for women with favorable admission Markwalder grades and mBI scores. Medical treatment with atorvastatin based on the specific 
